Skip to main content

abbvie-logo

AbbVie will buy venture-backed startup Stemcentrx  for $5.8 billion, beefing up the biopharma giant’s portfolio of cancer drugs.

The sale could be worth $4 billion more if  San Francisco-based Stemcentrx meets development milestones. Plus, as Business Insider reported, the startup has $400 million in the bank, potentially making the entire deal worth $10.2 billion.

{iframe}http://medcitynews.com/2016/04/abbvie-stemcentrx/?utm_source=MedCity+News+Subscribers&utm_campaign=104c95c020-MCN+Daily+Email&utm_medium=email&utm_term=0_5092836c41-104c95c020-408826397{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.